North central cancer treatment group (NCCTG) N0537: Phase II trial of vegf-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane

Clinical Breast Cancer

Volumn 12, Issue 6, 2012, Pages 387-391

  Sideras, Kostandinos ^a   Dueck, Amylou C ^b   Hobday, Timothy J ^a   Rowland, Kendrith M ^c   Allred, Jacob B ^a   Northfelt, Donald W ^b   Lingle, Wilma L ^a   Behrens, Robert J ^d   Fitch, Tom R ^b   Nikcevich, Daniel A ^e   Perez, Edith A ^f  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c Carle Cancer Center CCOP   (United States)

^d Iowa Oncology Research Association CCOP   (United States)

^e Essentia Health Duluth CCOP   (United States)

^f MAYO CLINIC   (United States)

Author keywords

Angiogenesis; Breast cancer; Cooperative group; Monoclonal antibody

Indexed keywords

AFLIBERCEPT; ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84869465976     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2012.09.007     Document Type: Article

References (27)

1. A. Gennari, P. Conte, R. Rosso Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies Cancer 104 2005 1742 1750
2. S. Dawood, K. Broglio, A.U. Buzdar Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review J Clin Oncol 28 2010 92 98
3. C. Desantis, R. Siegel, P. Bandi Breast cancer statistics, 2011 CA Cancer J Clin 61 2011 409 418
4. N. Ferrara Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications Semin Oncol 29 2002 10 14
5. N. Ferrara, H.P. Gerber, J. LeCouter The biology of VEGF and its receptors Nat Med 9 2003 669 676
6. M.A. Cobleigh, V.K. Langmuir, G.W. Sledge A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer Semin Oncol 30 2003 117 124
7. M.E. Van Meter, E.S. Kim Bevacizumab: current updates in treatment Curr Opin Oncol 22 2010 586 591
8. K. Miller, M. Wang, J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
9. N.J. Robert, V. Dieras, J. Glaspy Ribbon-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 29 2010 1252 1260
10. J. O'Shaughnessy, D. Miles, R.J. Gray A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC) J Clin Oncol 28 15 Suppl 2010 1005
11. H.J. Burstein, A.D. Elias, H.S. Rugo Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 26 2008 1810 1816
12. E.A. Perez, J.P. Spano Current and emerging targeted therapies for metastatic breast cancer Cancer 118 2012 3014 3025
13. G. Bianchi, S. Loibl, C. Zamagni Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer Anticancer Drugs 20 2009 616 624
14. J. Holash, S. Davis, N. Papadopoulos VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci U S A 99 2002 11393 11398
15. W.P. Tew, M. Gordon, J. Murren Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors Clin Cancer Res 16 2010 358 366
16. A.C. Lockhart, M.L. Rothenberg, J. Dupont Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors J Clin Oncol 28 2010 207 214
17. K.D. Miller, J.M. Trigo, C. Wheeler A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer Clin Cancer Res 11 2005 3369 3376
18. A. Moreno-Aspitia, R.F. Morton, D.W. Hillman Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336 J Clin Oncol 27 2009 11 15
19. S.K. Taylor, S. Chia, S. Dent A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium Oncologist 15 2010 810 818
20. A.M. Brufsky, S. Hurvitz, E. Perez Ribbon-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 29 2011 4286 4293
21. H.S. Rugo, A.T. Stopeck, A.A. Joy Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer J Clin Oncol 29 2011 2459 2465
22. J. Bergh, R. Greil, N. Voytko Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC) J Clin Oncol 28 Suppl 18s 2010 Abstract LBA1010
23. W.J. Gradishar, F. Dalenc, V.G. Kaklamani Multivariate analysis (MVA) of progression-free survival (PFS) in two phase IIb, multinational, double-blind, randomized, placebo (PL)-controlled trials evaluating sorafenib (SOR) plus standard chemotherapy in patients (pts) with HER2-negative locally advanced or metastatic breast cancer (BC) J Clin Oncol 28 Suppl 15s 2010 Abstract 1073
24. K.R. Broglio, D.A. Berry Detecting an overall survival benefit that is derived from progression-free survival J Natl Cancer Inst 101 2009 1642 1649
25. E.D. Saad, A. Katz, M. Buyse Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials J Clin Oncol 28 2010 1958 1962
26. D.W. Miles, S.L. deHaas, L. Dirix Plasma biomarker analysis in the AVADO phase III randomized study of first-line bevacizumab + docetaxel in patients with human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer Cancer Res 70 24 suppl 2010 Abstract P2-16-04
27. M.L. Maitland, G.L. Bakris, H.R. Black Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors J Natl Cancer Inst 102 2010 596 604